SARS-CoV2 InfectionLIPICORNCT05113836
LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2
An observational study of SARS-CoV2 Infection, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
In late 2019, a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of COVID-19 (COronaVIrus Disease-2019) in Hubei Province, China. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- SARS-CoV2 Infection
- What is being tested?
- Deep nasopharyngeal swab and Blood sample at D1, D3 and D7
- How many people
- 89 participants
- Where
- 1 siteFrance
- Study dates
- 6 Jan 2021to 8 Apr 2022
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Any patient hospitalised in intensive care for a COVID-19 infection. The health emergency of this pandemic and the potential therapeutic action of HDL particles justify the choice of this population for study.
Who may be able to join
- Age ≥ 18 years.
- Patient hospitalized in surgical intensive care unit for COVID-19 infection.
Who cannot join
- Pregnant or breastfeeding women
- CHILD B or C cirrhotic patients
- Moribund patients with an estimated life expectancy of less than 48 hours on admission to the ICU
- Subject protected by law under guardianship or curatorship
- No affiliation to a social security system
- Absence of signed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2 : LIPICOR Study
In late 2019, a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of COVID-19 (COronaVIrus Disease-2019) in Hubei Province, China. COVID-19 has become a pandemic with approximately 4.1 million confirmed cases as of May 2020 resulting in 280,000 deaths worldwide. Between 5 and 20% of patients hospitalized with SARS-CoV-2 infection are admitted to the ICU with a mortality ranging from 25 to 60% depending on the series. At present, there is no effective targeted therapy against this viral infection.
High-density lipoproteins (HDL) are nanoparticles made up of apolipoproteins, mainly apoA1, associated with phospholipids whose main function is the reverse transport of cholesterol from peripheral tissues to the liver. This property gives HDL a major cardiovascular protective effect. In addition to this effect, studies have highlighted a number of properties such as anti-inflammatory, anti-apoptotic, anti-thrombotic and anti-oxidant effects of these particles. Furthermore, it has been shown that HDL is able to bind and neutralize bacterial lipopolysaccharides (LPS), promoting their elimination.
Read more
During bacterial sepsis, a rapid decrease in plasma HDL cholesterol (HDL-C) concentration has been demonstrated, but also an inverse correlation between mortality and HDL-C concentration. In addition to the quantitative decrease in HDL during sepsis, dysfunctions of these particles have been described, such as major differences in size, or a notable alteration in protein composition with, in particular, more pro-inflammatory proteins. In this context of both quantitative and qualitative alteration of HDL, authors have tested the efficacy of injection of either reconstituted HDL (apoA1 + phosphatidylcholines) or peptides structurally similar to ApoA1 in animal models of sepsis and have demonstrated a protective effect on morbidity and mortality, with in particular a decrease in the inflammatory state induced by sepsis.
Low-density lipoproteins (LDL) can also neutralize LPS and observational studies have shown a decrease in the concentration of LDL cholesterol (LDL-C) during sepsis. The authors also showed that low LDL-C was associated with a poor prognosis in patients with sepsis.
During COVID-19-induced sepsis, a few studies have demonstrated a decrease in lipoprotein (HDL and LDL) concentration. More specifically, some authors have found an association between low lipoprotein concentrations and increased disease severity. To the best of the knowledge of the investigators, no study has specifically investigated particulate dysfunction of lipoproteins and in particular HDL during severe COVID-19 infections. On the other hand, as it has been described that lipoproteins and particularly HDL can bind bacterial components (LPS or LTA) favoring their clearance, it can be envisaged that these particles can also bind SARS-CoV-2 components, and this, in a more or less strong way depending on the virus strain.
The preliminary results of the investigators show that in sepsis, serum amyloid A (SAA) protein tends to replace apolipoprotein A1, making HDL dysfunctional. In addition, paraoxonase-1, an antioxidant enzyme mainly carried by HDL, is almost absent or degraded in septic patients. The SAA/PON-1 ratio could allow to assess the severity of COVID-19 damage and to reinforce a possible therapeutic strategy based on the supplementation of severe patients with apolipoprotein A1 and PON-1 rich HDL nanoparticles.
Main objective: To evaluate the functionality of HDL as a prognostic marker of mortality in COVID-19 patients in ICU. To do so, a quantification of the SAA/PON-1 ratio at plasma level and on isolated lipoproteins will be performed by ELISA.
- Conditions
- SARS-CoV2 Infection
- Being tested
- Deep nasopharyngeal swab, Blood sample at D1, D3 and D7
- Keywords
- Infecious disease, Sars-CoV2, COVID-19, LDL, HDL, SAA, PON-1
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Deep nasopharyngeal swabBiological
On admission in ICU, a deep nasopharyngeal swab will be performed (15mL).
Blood sample at D1, D3 and D7Biological
Specific samples for research and lipid analysis will be performed at D1, D3 and D7:
Assessments will be carried out on the same blood tube as the blood ionogram carried out as part of the usual management.
This means a 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7 (15mL in total).
| Study group | Role | What they receive |
|---|---|---|
| Any patient hospitalised in intensive care for a COVID-19 infection. | Any patient hospitalised in intensive care for a COVID-19 infection. The health emergency of this pandemic and the potential therapeutic action of HDL particles justify the choice of this population for study. Receives: Biological: Deep nasopharyngeal swab; Biological: Blood sample at D1, D3 and D7 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of concentration of Serum Amyloid A (SAA, inflammation protein) and paroxonase-1 (PON-1, antioxidant enzyme) in plasma and lipoproteins.
The primary endpoint will be the change of concentration of Serum Amyloid A (SAA, inflammation protein) and paroxonase-1 (PON-1, antioxidant enzyme) in plasma and lipoproteins. SAA and PON-1 will be quantified by ELISA directly in plasma and after isolating by ultracentrifugation lipoproteins (HDL and LDL) from Day 1 and Day 7.
Measured: Day 1 and Day 7.
Secondary outcomes (7)
Assessment of structural dysfunctions by proteomic approaches to lipoproteins during severe COVID-19 infections.
Assessment of structural dysfunctions by proteomic approaches to lipoproteins during severe COVID-19 infections.
Measured: Day 1, Day 3 and Day 7
Quantification of plasma HDL-C, LDL-C and triglyceride concentrations over time in patients hospitalized in ICU for severe COVID-19 infection.
Quantification of plasma HDL-C, LDL-C and triglyceride concentrations over time in
Measured: Day 1, Day 3 and Day 7
Study of HDL and LDL particle size profiles using the Lipo-print® technique.
Study of HDL and LDL particle size profiles using the Lipo-print® technique.
Measured: Day 1, Day 3 and Day 7
Comparison of pro- and anti-inflammatory cytokines levels, such as IL-1 beta, IL-6, TNF-alpha, IL-10 or IL-18, in patients according to their particle dysfunction data.
Comparison of pro- and anti-inflammatory cytokines levels, such as IL-1 beta, IL-6, TNF-alpha, IL-10 or IL-18, in patients according to their particle dysfunction data.
Measured: Day 1, Day 3 and Day 7
Comparison of particle dysfunction data to markers of endothelial dysfunction.
Comparison of particle dysfunction data to markers of endothelial dysfunction.
Measured: Day 1, Day 3 and Day 7
Comparison of lipid profiles to the genotype of COVID-19 strains.
Comparison of lipid profiles to the genotype of COVID-19 strains.
Measured: Day 1, Day 3 and Day 7
Search for binding of viral proteins to lipoproteins.
Search for binding of viral proteins to lipoproteins.
Measured: Day 1, Day 3 and Day 7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2021
- Study start6 Jan 2021
- Primary completion8 Apr 2022
- Study completion8 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SARS-CoV2 InfectionStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 89 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sebastien TANAKA, MD, PhD, Principal investigator, Assistance Publique - Hôpitaux de Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05113836
- Sponsor's protocol ID
- APHP20128
- Other IDs
- 2020-A02638-3
- Acronym
- LIPICOR
- Status last verified
- Jul 2026
- First submitted
- 11 Oct 2021
- Last updated
- 12 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Andrei S, Meilhac O, De Tymowski C, Snauwaert A, Stern J, Robert T, Lortat-Jacob B, Atchade E, Kantor E, Begue F, Montravers P, Tanaka S. Relationship between high-density lipoprotein cholesterol (HDL-C) concentration and ventilator-associated pneumonia in ICU COVID-19 patients. Anaesth Crit Care Pain Med. 2025 Aug;44(4):101535. doi: 10.1016/j.accpm.2025.101535. Epub 2025 May 1.
PubMed 40318849